TY - JOUR
T1 - Longitudinal antibody responses to peanut following probiotic and peanut oral immunotherapy in children with peanut allergy
AU - Hsiao, Kuang-Chih
AU - Ponsonby, Anne-Louise
AU - Ashley, Sarah
AU - Lee, Cassandra Yuen Yan
AU - Jindal, Lalita
AU - The PPOIT Study Team
AU - Tang, Mimi L. K.
AU - Loke, Paxton
AU - Axelrad, Christine
AU - Pitkin, Sigrid
AU - Robinson, Marnie
AU - Tey, Dean
AU - Su, Ee Lyn
N1 - Funding Information:
This study was funded by the Murdoch Childrens Research Institute and Australian Food Allergy Foundation. The Murdoch Childrens Research Institute is supported by the Victorian Government's Operational Infrastructure Support Program. Thermo Fisher supplied consumables for sIgE and sIgG4 testing. Kuang‐Chih Hsiao (KCH) received Australian Government Research Training Scholarship, Murdoch Childrens Research Institute Postgraduate Research Scholarship and the Royal Australasian College of Physicians Fellows Research Scholarship †
Funding Information:
This study was funded by the Murdoch Childrens Research Institute and Australian Food Allergy Foundation. The Murdoch Childrens Research Institute is supported by the Victorian Government's Operational Infrastructure Support Program. Thermo Fisher supplied consumables for sIgE and sIgG4 testing. Kuang-Chih Hsiao (KCH) received Australian Government Research Training Scholarship, Murdoch Childrens Research Institute Postgraduate Research Scholarship and the Royal Australasian College of Physicians Fellows Research Scholarship We thank Marion Nield, Sinead Flynn and Sandra Bengtsson for their technical assistance with ImmunoCAP assays.
Publisher Copyright:
© 2022 John Wiley & Sons Ltd.
PY - 2022/6
Y1 - 2022/6
N2 - Introduction: Probiotic and Peanut Oral Immunotherapy (PPOIT) is effective at inducing sustained unresponsiveness (SU) at end-of-treatment and this effect persists up to 4 years post-treatment, referred to as persistent SU. We sought to evaluate (i) how PPOIT altered peanut-specific humoral immune indices, and (ii) how such longitudinal indices relate to persistent SU. Methods: Longitudinal serum/plasma levels of whole peanut- and peanut component- (Ara-h1, -h2, -h3, -h8, -h9) specific-IgE (sIgE) and specific-IgG4 (sIgG4) antibodies were measured by ImmunoCAP and salivary peanut-specific-IgA (sIgA) by ELISA in children (n = 62) enrolled in the PPOIT-001 randomized trial from baseline (T0) to 4 years post-treatment (T5). Multivariate regression analyses of log-transformed values were used for point-in-time between group comparisons. Generalized estimating equations (GEE) were used for longitudinal comparisons between groups. Results: Probiotic and Peanut Oral Immunotherapy was associated with changes in sIgE and sIgG4 over time. sIgE levels were significantly reduced post-treatment [T5, PPOIT vs. Placebo ratio of geometric mean (GM): Ara-h1 0.07, p =.008; Ara-h2 0.08, p =.007; Ara-h3 0.15, p =.021]. sIgG4 levels were significantly increased by end-of-treatment (T1, PPOIT vs. Placebo ratio of GM: Ara-h1 3.77, p =.011; Ara-h2 17.97, p <.001; Ara-h3 10.42, p <.001) but levels in PPOIT group decreased once treatment was stopped and returned to levels comparable with Placebo group by T5. Similarly, salivary peanut sIgA increased during treatment, as early as 4 months of treatment (PPOIT vs. Placebo, ratio of GM: 2.04, p =.014), then reduced post-treatment. Conclusion: Probiotic and Peanut Oral Immunotherapy was associated with broad reduction in peanut-specific humoral responses which may mediate the clinical effects of SU that persists to 4 years post-treatment.
AB - Introduction: Probiotic and Peanut Oral Immunotherapy (PPOIT) is effective at inducing sustained unresponsiveness (SU) at end-of-treatment and this effect persists up to 4 years post-treatment, referred to as persistent SU. We sought to evaluate (i) how PPOIT altered peanut-specific humoral immune indices, and (ii) how such longitudinal indices relate to persistent SU. Methods: Longitudinal serum/plasma levels of whole peanut- and peanut component- (Ara-h1, -h2, -h3, -h8, -h9) specific-IgE (sIgE) and specific-IgG4 (sIgG4) antibodies were measured by ImmunoCAP and salivary peanut-specific-IgA (sIgA) by ELISA in children (n = 62) enrolled in the PPOIT-001 randomized trial from baseline (T0) to 4 years post-treatment (T5). Multivariate regression analyses of log-transformed values were used for point-in-time between group comparisons. Generalized estimating equations (GEE) were used for longitudinal comparisons between groups. Results: Probiotic and Peanut Oral Immunotherapy was associated with changes in sIgE and sIgG4 over time. sIgE levels were significantly reduced post-treatment [T5, PPOIT vs. Placebo ratio of geometric mean (GM): Ara-h1 0.07, p =.008; Ara-h2 0.08, p =.007; Ara-h3 0.15, p =.021]. sIgG4 levels were significantly increased by end-of-treatment (T1, PPOIT vs. Placebo ratio of GM: Ara-h1 3.77, p =.011; Ara-h2 17.97, p <.001; Ara-h3 10.42, p <.001) but levels in PPOIT group decreased once treatment was stopped and returned to levels comparable with Placebo group by T5. Similarly, salivary peanut sIgA increased during treatment, as early as 4 months of treatment (PPOIT vs. Placebo, ratio of GM: 2.04, p =.014), then reduced post-treatment. Conclusion: Probiotic and Peanut Oral Immunotherapy was associated with broad reduction in peanut-specific humoral responses which may mediate the clinical effects of SU that persists to 4 years post-treatment.
KW - antibody responses
KW - desensitization
KW - oral immunotherapy
KW - peanut allergy
KW - probiotic
KW - remission
KW - sustained unresponsiveness
UR - http://www.scopus.com/inward/record.url?scp=85130985327&partnerID=8YFLogxK
U2 - 10.1111/cea.14146
DO - 10.1111/cea.14146
M3 - Article
C2 - 35403286
AN - SCOPUS:85130985327
SN - 0954-7894
VL - 52
SP - 735
EP - 746
JO - Clinical and Experimental Allergy
JF - Clinical and Experimental Allergy
IS - 6
ER -